
PRIV.-DOZ. DR. MED. MARTIN ALEXANDER WALTER

I. CURRICULUM VITAE

A. Personal Data

Date and Place of Birth: October 17th 1974 in West-Berlin, D
Citizenship: German
Marital status: Engaged to Rebecca Dumont, MD
Languages: German (*native*), English (*fluent*), Latin (*adequate*)
Private Address: Wasserwerksgasse 35
CH-3011 Bern
Phone: +41 (79) 885 1502
Professional Address: Institute of Nuclear Medicine
University Hospital
Freiburgstrasse 4
CH-3010 Bern
Phone: +41 (31) 63-23542
Fax: +41 (31) 63-23137
Email: m.a.walter@gmx.net

B. Professional Curriculum

Since 2011 Dual Appointment: Head of Research Laboratories and Attending Physician, Nuclear Medicine, University Hospital, Bern, CH
(Head: Prof. Dr. med Thomas Krause) and
Assistant Professor, Department of Molecular & Medical Pharmacology, UCLA, California, USA
(Head: Prof. Dr. med. Michael E. Phelps)

2010 - 2011 Head of Research Laboratories and Attending Physician, Nuclear Medicine, University Hospital, Bern, CH
(Head: Prof. Dr. med Thomas Krause)

2009 - 2010 Attending Physician, Nuclear Medicine, University Hospital, Basel, CH
(Head: Prof. Dr. med Jan Müller-Brand)

2007 - 2009 Postdoctoral Research Fellowship, Department of Molecular & Medical Pharmacology, UCLA, California, USA
(Head: Prof. Dr. med. Michael E. Phelps)

2006 Final Board Certification Exam in Nuclear Medicine (FMH)

2004 - 2007 50% Resident, Nuclear Medicine, University Hospital, Basel, CH
50% Research Fellowship, Division of Endocrinology, University Hospital, Basel, CH
(Mentor: Prof. Dr. med. Beat Müller)

2004 First Board Certification Exam in Nuclear Medicine (FMH)

2003 - 2004 50% Resident, Nuclear Medicine, University Hospital, Basel, CH
50% Postdoctoral Research Fellowship, Radiological Chemistry, University Hospital, Basel, CH
(Head: Prof. Dr. phil. Helmut R. Mäcke)

2002 - 2003 Resident, Nuclear Medicine, University Hospital, Basel, CH

2001 Final Medical Examination (University of Münster, D)
MD Thesis on "Imaging of Minor Head Injury"
(Thesis Directors: Prof. Wassmann H and Prof. Heindel W, Münster, D)

1995 - 2001 Medical Schools, Universities of Münster, D; London, UK; Zürich, CH

1981 - 1994 Elementary School and High School, Bielefeld, D

C. Diplomas and Certifications

- Venia Docendi for Nuclear Medicine (Privatdozent, Habilitation; 2010)
- Certification of Expertise in Radiation Protection (Strahlenschutz-Sachverständiger; 2008)
- Good Clinical Practice Certification for Principal Investigators (2006)
- FELASA B+C for Conducting and Directing Animal Experiments (Tierversuchs-Leiter; 2006)
- Final Nuclear Medicine Board Examination (FMH; 2006)
- MD Diploma, Medical School, Universities of Münster, D (2001)

D. Memberships

- Swiss Society of Neuroendocrine Cancers, SwissNET (since 2011)
- European Foundation for Clinical Nanomedicine, CLINAM (since 2009)
- European Association of Nuclear Medicine, EANM (since 2007)
- American Thyroid Association, ATA (since 2005)
- Swiss Society of Nuclear Medicine, SGNM (since 2003)

E. Editorial Duties

- Journal of Nuclear Medicine (Impact Factor 7.0) (Editorial Board, since 2011)
- World Journal of Radiology (Editorial Board, since 2010)
- The Open Nuclear Medicine Journal (Editorial Board, since 2008)

F. Teaching Activities

- Since 2009 Student Lectures: 'Imaging in Endocrinology', *Medical Faculty, University Basel*
- 2007-2009 Student Lectures: 'Principles of Nuclear Medicine', *Medical Faculty, UCLA, Los Angeles, USA*
- 2002-2007 Teaching Assistant in Student Courses: 'Introduction to Nuclear Medicine', *Medical Faculty University Basel*

G. Awards

- 1st Price Poster Award. 4th Annual Meeting of The Society of Molecular Imaging, Cologne, 2005
- EANM Young Investigator Award. Annual Congress of the European Association of Nuclear Medicine, Copenhagen, 2007
- DGN Thyroid Research Award. Annual Congress of the German Association of Nuclear Medicine, Leipzig, 2008
- SNM Molecular Imaging Abstract Track 2nd Price. Annual Congress of the Society of Nuclear Medicine, New Orleans, 2008
- SNM Travel Award. Annual Congress of the Society of Nuclear Medicine, New Orleans, 2008
- WMIC Travel Award. World Molecular Imaging Congress, Nice, 2008
- WMIC Travel Award. World Molecular Imaging Congress, Nice, 2008
- DGN Thyroid Research Award. Joint Meeting of the German, Austrian and Swiss Societies of Nuclear Medicine, Bregenz, 2011
- EANM Eckert & Ziegler Abstract Award. Annual Meeting of the European Society of Nuclear Medicine, Birmingham, 2011

H. Supervision of M.D. Theses (n=11)

II. BIBLIOGRAPHY - PUBLICATION LIST

IMPACT FACTOR SUM: 327.9 (BASED ON THE ISI JOURNAL CITATION REPORT 2010)

SUM OF TIMES CITED: 630 (BASED ON THE ISI WEB OF KNOWLEDGE, DECEMBER 20th 2011)

H-INDEX: 14 (BASED ON THE ISI WEB OF KNOWLEDGE, DECEMBER 20th 2011)

H-INDEX: 15 (BASED ON GOOGLE SCHOLAR, DECEMBER 20th 2011)

A. Original Full Publications (Peer-Reviewed)	IF
1. <u>Walter MA</u> , Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Müller-Brand J and Müller B. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and posttherapeutic outcome. Eur J Clin Invest 2004;34(5):365-70	2.7
2. <u>Walter MA</u> , Christ-Crain M, Müller B and Müller-Brand J. Radioiodine uptake and thyroid hormone levels on or off simultaneous carbimazole medication: a prospective paired comparison. Nuklearmed - Nucl Med 2005;44(1):33-36	1.8
3. Ginj M, Chen J, <u>Walter MA</u> , Eltschinger V, Reubi JC and Mäcke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005;11(3):1136-45	7.3
4. Schlegel PM, <u>Walter MA</u> , Kloska SP, Rieger B, Fischer RJ, Wassmann H and Heindel W. Is the Canadian CT Head Rule for minor head injury applicable for patients in Germany? RoFo 2005;177(6):872-6.	2.5
5. <u>Walter MA</u> , Melzer RA, Schindler C, Müller-Brand J, Tyndall A and Nitzsche EU. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005;32(6):674-81	5.0
6. Storch D, M. Behe, <u>Walter MA</u> , J. Chen P, Powell, R. Mikohajczak and Maecke HR. Evaluation of [99mTc/EDDA/HYNIC]Octreotide Derivatives Compared with [¹¹¹ In-DOTA ₀ ,Tyr ₃ , Thr ₈]Octreotide and [¹¹¹ In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization? J Nucl Med 2005;46(9):1561-9.	7.0

-
7. Schiavi F, Boedeker CC, Bausch B, Peçzkowska M, Gomez CF, Straßburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M, Walter MA, Forrer F, Välimäki M, Schipper J, Walz MK, Pigny P, Bauters C, Willet-Brozick JE, Baysal BE, Januszewicz A, Eng C, Opocher G and Neumann HPH. Predictors and Prevalence of Paraganglioma Syndrome associated with Mutations of the *SDHC* Gene. **JAMA** 2005;294(16):2057-63.
Erratum: JAMA. 2006;295(6):628
- Comment:** JAMA. 2006;295(6):625
8. Walter MA, Seboek D, Demougin P, Bubendorf L, Oberholzer M, Müller-Brand J and Müller B. Extraction of High-Integrity RNA Suitable for Microarray Gene Expression Analysis From Long-Term Stored Rapid-Frozen Human Thyroid Tissues. **Pathology** 2006;38(3):249–253
9. Walter MA, Christ-Crain M, Schindler C, Müller-Brand J and Müller B. Outcome of Radioiodine Therapy Without, On or 3 Days Off Carbimazole: A Prospective Interventional 3-Group-Comparison. **Eur J Nucl Med Mol Imaging** 2006;33(6):730-7
10. Antunes P, Ginj M, Walter MA, Chen J, Reubi JC and Maecke HR. Influence of Different Spacers on the Biological Profile of a DOTA-Somatostatin Analogue. **Bioconjugate Chem** 2007;18(1):84-92
11. Walter MA, Briel M, Christ-Crain M, Bonnema S, Connell J, Cooper DS, Bucher HC, Müller-Brand J and Müller B. Effects of Antithyroid Drugs on Radioiodine Treatment: Systematic Review and Meta-Analysis of Randomised Controlled Trials. **BMJ** 2007;334(7592):514-7
- Editorial:** Toft A, Sandeep TC. Radioiodine Treatment of Hyperthyroidism. **BMJ** 2007;334(7592):483-4.
- Comment:** Razvi S, Pearce SH. Do antithyroid drugs influence outcome after radioiodine therapy for hyperthyroidism? **Nat Clin Pract Endocrinol Metab.** 2007;3(9):628-9.
- Comment:** McDermott MT
Clinical Thyroidology 2007;19(2):25
12. Bausch B, Borozdin W, Mautner VF, Hoffmann MM, Boehm D, Robledo M, Cascon A, Harenberg T, Schiavi F, Pawlu C, Peczkowska M, Letizia C, Calvieri S, Arnaldi G, Klingenberg-Noftz RD, Reisch N, Fassina A, Brunaud L, Walter MA, Mannelli M, MacGregor G, Palazzo FF, Barontini M, Walz MK, Kremens B, Brabant G, Pfäffle R, Koschker AC, Lohofner F, Mohaupt M, Gimm O, Jarzab B, McWhinney SR, Opocher G, Januszewicz A, Kohlhase J, Eng C and Neumann HP. Germline *NF1* Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1
J Clin Endocrinol Metab 2007;92(7):2784-2792
-

-
13. Walter MA, Turtschi C, Schindler C, Minnig P, Müller-Brand J and Müller B. 7.0
The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study
J Nucl Med 2007;48(10):1620-1625
14. Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Maecke HR, Müller-Brand J and Walter MA. 7.3
Response to [⁹⁰Yttrium-DOTA]-TOC Treatment is Associated with Long-Term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial
Clin Cancer Res 2007;13(22):6696-6702
- Awarded:** DGN Thyroid Research Award 2008
15. Good S*, Walter MA*, Waser B, Wang X, Müller-Brand J, Behe MP, Reubi JC and Mäcke HR. 5.0
Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours.
* Good S and Walter MA contributed equally to the manuscript
Eur J Nucl Med Mol Imaging 2008;35(10):1868-77.
16. Pęczkowska M, Erlic Z, Hoffmann MM, Furmanek M, Ćwikła J, Kubaszek A, Prejbisz A, Szutkowski Z, Kawecki A, Chojnowski K, Lewczuk A, Litwin M, Szyfter W, Walter MA, Sullivan M, Eng C, Januszewicz A and Neumann HPH. 6.5
Impact of Screening Kindreds for *SDHD* p.Cys11X as a Common Mutation Associated with Paraganglioma Syndrome Type 1
J Clin Endocrinol Metab 2008;93(12):4818-4825.
17. Walter MA, Schindler C, Christ-Crain M, Müller-Brand J and Müller B. 2.7
Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.
Eur J Clin Invest 2009;39(1):51-7.
18. Iten F, Müller B, Schindler C, Rasch H, Rochlitz C, Oertli D, Maecke HR, Müller-Brand J and Walter MA. 5.1
Response, Time to Relapse and Survival after Radiopeptide Therapy with [⁹⁹Y-DOTA]-TOC for Progressive De-Differentiated Thyroid Carcinoma
Cancer 2009;115(10):2052-2062
- Awarded:** EANM Young Investigator Award 2007
19. Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG and Yeh MW. 7.0
[F-18] FDOPA PET and PET-CT Accurately Localize Pheochromocytomas
J Nucl Med 2009;50(4):513-519.
20. Laing R, Walter MA, Campbell DO, Herschman H, Satyamurthy N, Phelps ME, Czernin J, Witte O and Radu CG. 9.8
Noninvasive Prediction of Tumor Responses to Gemcitabine Using Positron Emission Tomography
Proc Natl Acad Sci U S A. 2009;106(8):2847-52.
- Awarded:** WMIC Travel Award 2008
-

-
21. Neumann HP, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, Schiavi F, Falcioni M, Kwok P, Bauters C, Lampe K, Fischer M, Edelman E, Benn DE, Robinson BG, Wiegand S, Rasp G, Stuck BA, Hoffmann MM, Sullivan M, Sevilla MA, Weiss MM, Peczkowska M, Kubaszek A, Pigny P, Ward RL, Learoyd D, Croxson M, Zabolotny D, Yaremchuk S, Draf W, Muresan M, Lorenz RR, Knipping S, Strohm M, Dyckhoff G, Matthias C, Reisch N, Preuss SF, Esser D, Walter MA, Kaftan H, Stöver T, Fottner C, Gorgulla H, Malekpour M, Zarandy MM, Schipper J, Brase C, Glien A, Kühnemund M, Koscielny S, Schwerdtfeger P, Välimäki M, Szyfter W, Finckh U, Zerres K, Cascon A, Opocher G, Ridder GJ, Januszewicz A, Suarez C and Eng C. 8.2
Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out
Cancer Res 2009;69(8):3650-6.
22. Boedeker CC, Erlic Z, Richard S, Kontny U, Gimenez-Roqueplo AP, Cascon A, Robledo M, de Campos JM, van Nederveen FH, de Krijger RR, Burnichon N, Gaal J, Walter MA, Reschke K, Wiech T, Weber J, Rückauer K, Plouin PF, Darrouzet V, Giraud S, Eng C and Neumann HP. 6.5
Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2
J Clin Endocrinol Metab 2009;94(6):1938-44.
23. Walter MA, Meier C, Radimerski T, Iten F, Kränzlin M, Müller-Brand J, de Groot JW, Kema IP, Links TP and Müller B. 5.1
Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer.
Cancer 2010;116(1):31-40.
24. Chinnadurai P, Berg S, Nicolas G, Walter MA, Rasch H, Mueller-Brand J and Kneifel S. -
Monitoring and Predicting Response to Peptide Receptor Radionuclide Therapy: A Quantitative SPECT-CT Based Analysis
The Open Nuclear Medicine Journal 2010;2:6-14
25. Walter MA, Hildebrandt IJ, Hacke K, Kesner AL, Kelly O, Lawson GW, Phelps ME, Czernin J, Weber WA and Schiestl RH. 7.0
Small-Animal PET/CT for Monitoring the Development and Response to Chemotherapy of Thymic Lymphoma in Trp53(-/-) Mice
J Nucl Med J 2010;51(8):1285-92.
26. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Ngheimphu L, Lai A, Phelps ME and Chen W. 7.0
Correlation of 6-¹⁸F-Fluoro-L-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas
J Nucl Med J 2010;51(10):1532-8.
27. Grozinsky-Glasberg S, Barak D, Fraenkel M, Müller-Brand J, Walter MA, Eckstein J, Applebaum L, Shimon I and Gross DJ. 5.1
Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas
Cancer 2011;117(7):1377-85
-

-
28. Kretzschmar M, Wiewiorski M, Rasch H, Jacob AL, Bilecen D, Müller-Brand J, Walter MA and Valderrabano V. 2.9
^{99m}Tc-DPD-SPECT/CT predicts the outcome of imaging-guided diagnostic anaesthetic injections: A prospective cohort study
Eur J Radiology 2011 *In Print*
29. Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, Toledo SP, Toledo RA, Tavares MR, Alevizaki M, Mian C, Siggelkow H, Hüfner M, Wohlk N, Opocher G, Dvořáková S, Bendlova B, Czetwertynska M, Skasko E, Barontini M, Sanso G, Vorländer C, Maia AL, Patocs A, Links TP, de Groot JW, Kerstens MN, Valk GD, Miehle K, Musholt TJ, Biarnes J, Damjanovic S, Muresan M, Wüster C, Fassnacht M, Peczkowska M, Fauth C, Golcher H, Walter MA, Pichl J, Raue F, Eng C and Neumann HP. 6.0
(for the International RET Exon 10 Consortium)
Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline *RET* mutations located in exon 10
Human Mutation 2010;32(1):51-8.
30. Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Damoiseaux RD, Phelps ME, Czernin J and Weber WA. 7.0
Metabolic imaging allows early prediction of response to RET kinase inhibition
J Nucl Med 2010;52(2):231-40
31. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Mäcke HR, Rochlitz C, Müller-Brand J and Walter MA. 19.0
[⁹⁰Yttrium-DOTA]-TOC in Metastasized Neuroendocrine Cancers: Response, Survival and Long-Term Toxicities
J Clin Oncol 2011;29(17):2416-23.

Featured: Hutchinson, L. Radiopeptide therapy improves outcomes for neuroendocrine cancers. *Nat. Rev. Clin. Oncol.* 8, 384 (2011).
32. Walter F, Hall T, Auerbach MA, Walter MA, Dunkelmann S, Federman N and Czernin J. 1.0
Is there a need for dedicated bone imaging in addition to [¹⁸F]FDG PET/CT imaging in paediatric sarcoma patients?
Journal of Pediatric Hematology and Oncology 2011 *In Print*
33. Walter F, Federman N, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA and Czernin J. 0.8
¹⁸F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients
Pediatr Hematol Oncol 2011;28(7):579-87.
34. Fuchs M, Briel M, Daikeler T, Walker UA, Rasch H, Berg S, Ng QKT, Raatz H, Jayne D, Kötter I, Blockmans D, Cid MC, Prieto-González S, Lamprecht P, Salvarani C, Karageorgaki Z, Watts R, Luqmani R, Jan Müller-Brand, Tyndall A and Walter MA. 5.0
The impact of ¹⁸F-FDG-PET on the management of patients with suspected large vessel vasculitis
Eur J Nucl Med Mol Imaging 2011 *In Print*
35. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu L, Wagle N, Fueger B, Phelps ME and Czernin J. 7.0
Impact of ¹⁸F-DOPA PET/CT Imaging on managing patients with brain tumors: the referring physician's perspective
J Nucl Med 2011 *In Print*
-

-
36. Villard L, Romer A, Marincek N, Brunner P, Koller M, Schindler C, Ng QKT, Mäcke HR, Müller-Brand J, Rochlitz C, Briel M and Walter MA.
A Cohort Study on [⁹⁰Yttrium-DOTA]-TOC versus [⁹⁰Yttrium-DOTA]-TOC plus [¹⁷⁷Lutetium-DOTA]-TOC in Metastasized Neuroendocrine Cancers
J Clin Oncol 2012 *In Print* 19.0
37. Ng QKT, Segura T, Ben-Shlomo A, Krause T, Mindt TL and Walter MA.
Synthesis, Gallium-68 Labeling and Biological Evaluation of DOTA-, NODAGA- and Desferrioxamine-modified Nanoparticles
Under Review
38. Romer A, Seiler D, Marincek N, Brunner P, Koller M, Ng QKT, Mäcke HR, Müller-Brand J, Rochlitz C, Briel M, Schindler C and Walter MA.
Somatostatin-based Radiopeptide Therapy with [¹⁷⁷Lutetium-DOTA]-TOC versus [⁹⁰Yttrium-DOTA]-TOC in Neuroendocrine Cancers
Under Review
39. Neumann HPH, Ni Y, Sullivan M, Chen JL, Winter A, Moline J, Rybicki LA, Boedeker CC, Patocs A, Hoffmann MM, Glaser B, Fraenkel M, Fottner C, Bertz H, Lorenz K, Walter MA, Moeller LC, Reisch N, Nies C, Ridder GJ, Glasker S, Peczkowska M, Yaremchuk S, Weryha G, Falcioni M, Golcher H, Brase C, Preuss SF, Kwok P, Schaeffler A, Wiegand S, Schott M, Malekpour M, Zarandy MM, Ploeckinger U, Jumah MD, Klose S, Kann PH, Müssig K, Fassnacht M, Glien A, Lang S, Kaftan H, Isermann B, Seufert J, Schmid KW, Wiech T, Lendvai N, Valimakki M, Edelman E, Buchta M, Bacher J, Blüm T, Berisha G, Orloff MS, Racz K, Januszewicz A, Walz MK and Eng C
Prevalence, Penetrance and Gene-Specific Presentations of Pheochromocytomas and Paragangliomas
Under Review

B. Correspondence and Case Reports	IF
40. <u>Walter MA</u> , Nitzsche EU and Müller-Brand J. Enhancement of Radioiodine Uptake in Hyperthyroidism by Administration of Hydrochlorothiazide Eur J Nucl Med Mol Imaging 2003;30(3):474	5.0
41. <u>Walter MA</u> , Muller B and Müller-Brand J. Does an Individual Estimation of Half-life improve the Results of Radioiodine Therapy of Graves' Disease? Nuklearmed - Nucl Med 2003;42(3):N29	1.8
42. <u>Walter MA</u> , Burger P, Pfisterer M, Müller-Brand J and Zellweger M. Situs Inversus Completus Eur J Nucl Med Mol Imaging 2003;30(8):1202	5.0
43. <u>Walter MA</u> , Christ-Crain M, Müller B and Müller-Brand J. The Detrimental Effect of Anti-thyroid Drugs on the Outcome of Radioiodine Therapy is not directly due to a Decreased Radioiodine Uptake. Nucl Med Commun 2005;26(19):70	1.4
44. <u>Walter MA</u> , Melzer RA, Graf M, Tyndall A, Müller-Brand J and Nitzsche EU. [¹⁸ F]FDG-PET of Giant-Cell Aortitis Rheumatology 2005;0:1–2	4.2
45. Hodek-Wuerz R, <u>Walter MA</u> and Müller-Brand J. Puzzling Intestinal Uptake in ^{99m} Tc-DPD Bone Scintigraphy Nuklearmed – Nucl Med 2006;45(4):N41	1.8
46. <u>Walter MA</u> , Wild D, Rasch H , Müller-Brand J, Müller B and Bilz S. Co-Registered ¹³¹ Iodine-SPECT/CT Reveals De-Differentiation in a Metastatic Follicular Thyroid Carcinoma Thyroid 2006;16(10):1063-4	4.3
47. <u>Walter MA</u> , Müller-Brand J and Müller B. Antithyroid Drugs and Radioiodine and the Absence of Evidence J Nucl Med 2007;48(8):1403	7.0
48. <u>Walter MA</u> , Christ-Crain M, Müller B. Graves' Disease New England Journal of Medicine 2008;359(13):1407	53.5
49. Abed M, Adelbrecht C, Amado Señarís JA, Amighi J, Ankersmit HJ, de Berrazueta JR, Bobbioni-Harsch E, Boyle K, Buechler C, Buemi M, Cernaro V, Chang JK, Chen CH, Wen-Ping C, Cuocolo A, Dullaart RPF, Ghafourifar P, Guzik P, Gyöngyösi M, Hoffmann MM, Jurado J, Kytö V, Lang F, Lichtenauer M, Lin ZY, Minami Y, Montero D, Mookadam F, Nicolai E, Pacher R, Rahimian R, Satoh M, Saukko P, Selzer E, Shyu K, Sztajzel J, Vinet A, <u>Walter MA</u> , Willmann M, Winkler K, Wykretowicz A, Koker MY and Ybarra J. Research Update for Articles Published in EJCI in 2009 Eur J Clin Invest. 2011;41(11):1149-1163	2.7

C. Other Original Work, Editorials and Invited Reviews **IF**

50. Walter MA. -
Die Canadian Head Rule für Patienten mit leichtem Schädelhirntrauma: ist die Anwendung in Münster sinnvoll?
MD Thesis, Deutsche Nationalbibliothek (www.d-nb.de) 2004
51. Walter MA, Melzer RA, Schindler C, Müller-Brand J, Tyndall A and Nitzsche EU. -
The Value of [¹⁸F]FDG-PET in the Assessment of Activity, Diagnose and Extent in Large Vessel Vasculitis
Elsevier's Yearbook of Nuclear Medicine 2006;281-2
52. Walter MA. -
[¹⁸F]FDG-PET in Large Vessel Vasculitis
PET Clinics of North America 2006;1(2):179-189
53. Iten F, Müller B, Müller-Brand J and Walter MA. -
The Systemic Radionuclide based Treatment of Metastasized Medullary Thyroid Cancer
Swiss Medical Forum 2007;7:21-22
54. Hauser A and Walter MA. -
[¹⁸F]FDG-PET in Large Vessel Vasculitis
Der Nuklearmediziner 2007;30:1-8
55. Walter MA. 2.2
[¹⁸F]FDG-PET in Large Vessel Vasculitis
Radiologic Clinics of North America 2007;45: 735–744
56. Mindt TL and Walter MA. -
Nanoprobes – size does matter!
Swiss Medical Forum 2009;9(51–52):946-947
57. Klaeser B, Walter MA and Krause T. -
Knochenszintigraphie und SPECT/CT bei orthopädischen Fragestellungen
Der Nuklearmediziner 2011,34(1):28-34

D. Book Chapters

58. Dumont RA, Müller-Brand J and Walter MA.
Chapter 27: 'Treatment of Progressive Dedifferentiated and Medullary Thyroid Cancer with Radiolabeled Somatostatin Analogues'
In **Therapeutic Nuclear Medicine** (Edited by R.P. Baum)
2011 In Print
59. Dumont RA, Müller-Brand J and Walter MA.
Chapter 4.2.: 'Nuclear Medicine Imaging of the Thyroid'
In **Surgery of Thyroid and Parathyroid Glands** (Edited by D. Oertli)
2011 In Print
60. Dumont RA, Müller-Brand J and Walter MA.
Chapter 22.1 : 'Radioisotope Treatment of Thyroid Tumors'
In **Surgery of Thyroid and Parathyroid Glands** (Edited by D. Oertli)
2011 In Print
61. Ng QTK, Klaeser B, Walker U, Walter MA.
Chapter 3: [¹⁸F]FDG-PET in Large Vessel Vasculitis
In **Advances in the Diagnosis and Treatment of Vasculitis** (Edited by L.M. Amezcua-Guerra)
ISBN 978-953-307-786-4
2011